Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Corcept Therapeutics (CORT) EBIT Margin (2016 - 2025)

Historic EBIT Margin for Corcept Therapeutics (CORT) over the last 13 years, with Q3 2025 value amounting to 4.92%.

  • Corcept Therapeutics' EBIT Margin fell 206100.0% to 4.92% in Q3 2025 from the same period last year, while for Sep 2025 it was 8.85%, marking a year-over-year decrease of 139600.0%. This contributed to the annual value of 20.29% for FY2024, which is 19500.0% down from last year.
  • Corcept Therapeutics' EBIT Margin amounted to 4.92% in Q3 2025, which was down 206100.0% from 13.72% recorded in Q2 2025.
  • Corcept Therapeutics' 5-year EBIT Margin high stood at 37.69% for Q3 2021, and its period low was 2.17% during Q1 2025.
  • For the 5-year period, Corcept Therapeutics' EBIT Margin averaged around 22.97%, with its median value being 24.72% (2021).
  • Its EBIT Margin has fluctuated over the past 5 years, first surged by 90600bps in 2021, then tumbled by -206100bps in 2025.
  • Quarter analysis of 5 years shows Corcept Therapeutics' EBIT Margin stood at 37.1% in 2021, then tumbled by -41bps to 21.83% in 2022, then grew by 7bps to 23.39% in 2023, then tumbled by -41bps to 13.89% in 2024, then plummeted by -65bps to 4.92% in 2025.
  • Its EBIT Margin stands at 4.92% for Q3 2025, versus 13.72% for Q2 2025 and 2.17% for Q1 2025.